Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
Francesca Fazio,
Luca Franceschini,
Valeria Tomarchio,
Angela Rago,
Maria Grazia Garzia,
Luca Cupelli,
Velia Bongarzoni,
Alessandro Andriani,
Svitlana Gumenyuk,
Agostino Tafuri,
Agostina Siniscalchi,
Alfonso Piciocchi,
Paolo De Fabritiis,
Luca De Rosa,
Tommaso Caravita di Toritto,
Ombretta Annibali,
Maria Cantonetti,
Maria Teresa Petrucci
Affiliations
Francesca Fazio
Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of RomeSapienza Università di Roma
Luca Franceschini
Transplant Network, Hematology‐Stem Cell Transplant Unit Rome Italy
Valeria Tomarchio
Department of Haematology, University Campus Biomedico Rome Italy
Angela Rago
ASL RM/A UOSD Ematologia Asl Roma 1 Rome Italy
Maria Grazia Garzia
Department of Hematology, Hematology San Camillo Forlanini Hospital Rome Italy
Luca Cupelli
Department of Hematology, Hematology Ospedale Sant'Eugenio Rome Italy
Velia Bongarzoni
Department of Hematology San Giovanni‐Addolorata Hospital Rome Italy
Alessandro Andriani
Department of Hematology Ospedale Fabrizio Spaziani Rome Italy
Svitlana Gumenyuk
Haematology and Stem Cell Transplant Regina Elena National Cancer Institute Rome Italy
Agostino Tafuri
Azienda Ospedaliera Sant'Andrea Rome Italy
Agostina Siniscalchi
S. Eugenio Hospital Institute of Haematology Rome Italy
Alfonso Piciocchi
Data Center, Italian Group for Adult Hematologic Diseases, (GIMEMA) Rome Italy
Paolo De Fabritiis
Department of Haematology Ospedale Sant'Eugenio Rome Italy
Luca De Rosa
Hematology and Bone Marrow Transplantation Unit Azienda Ospedaliera San Camillo‐Forlanini Rome Italy
Tommaso Caravita di Toritto
Department of Hematology, ASL Roma 1 Rome Italy
Ombretta Annibali
Department of Haematology Campus Bio‐Medico University of Rome Rome Italy
Maria Cantonetti
Chair of Hematology, Universita Tor Vergata Rome Italy
Maria Teresa Petrucci
Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of RomeSapienza Università di Roma
Abstract The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression‐free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment‐emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real‐life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.
